View all veterinary jobs
Cellular haemoglobin concentration mean gives clinicians a direct measurement of the average haemoglobin concentration within individually analysed red blood cells.
Unlike mean corpuscular haemoglobin concentration, which is a calculated value, cellular haemoglobin concentration mean is measured optically, which Zoetis says provides a more reliable indicator needed when a patient is anaemic and when endogenous interferents, such as haemolysis, are present.
The expansion also includes plateletcrit (PCT) measurement.
Plateletcrit provides the volume percentage of blood occupied by platelets – functionally similar to how haematocrit (HCT) reflects the red blood cell fraction.
Zoetis says PCT helps clinicians better assess platelet production, consumption, and evidence of destruction.
Both new parameters are expected to be available to Vetscan OptiCell users in 2026.
https://www.zoetisdiagnostics.com/uk
The sessions are aimed at vets, vet nurses, SQPs and RAMAs involved in anthelmintic prescribing, and are designed to support implementation of new sustainable equine parasite control guidelines from the BEVA and Canter.
The webinars will be presented by Professor Jacqui Matthews, an RCVS Recognised Specialist in Parasitology, and Dr Wendy Talbot, Zoetis RCVS and European Specialist in Internal Medicine.
Participants can submit real-world case scenarios for discussion by emailing details to wendy.talbot@zoetis.com at least four weeks before each webinar. There is no obligation for case submitters to speak during the webinar.
The remaining scheduled sessions are:
The webinar series can be recorded as self-reflective CPD.
https://canterforhorses.org.uk/guidelines/
https://www.beva.org.uk/Resources/Medicines/Anthelmintic-Toolkit
The survey of 2,256 horse owners examined current EHV vaccination rates, owner understanding of the disease, and perceived barriers to uptake.
While 95% of respondents reported vaccinating for influenza and tetanus, only 17% said they vaccinate for EHV despite 86% believing vaccination significantly reduces disease spread.
The most commonly cited reason for not vaccinating against EHV was that their vet had not recommended it, reported by 65% of respondents.
40% said they were unaware that a vaccine was available.
Although 98% recognised equine gatherings as a risk factor for EHV transmission, more than a quarter did not fully understand how the virus spreads or the risks posed to their horse.
75% reported frequently taking horses off their home premises.
94% understood that nose-to-nose contact could transmit the virus.
However, one in four did not know EHV could also spread via airborne droplets, shared equipment, handlers or bedding.
78% of owners not currently vaccinating said they would be likely to do so after learning more about the potential impact of the disease.
Zoetis National Equine Veterinary Manager Dr Wendy Talbot said the findings reinforced the influence of veterinary recommendation in reducing the risk of EHV outbreaks.
Reference
Veterinary surgeons will also be asked to verify each horse’s health status via a brief questionnaire (around 4 minutes).
The results of the questionnaires will be used to develop a scoring algorithm to measure the impact of health on a horse’s quality of life.
Zoetis says support from the veterinary profession is going to be pivotal to its ability to deliver a valid and reliable measurement tool, one that has the potential to transform the welfare of horses worldwide.
To that end, vets who contribute will gain early insight into a scientifically validated HRQL instrument designed to:
If you would like to participate, of if you would like more information contact Dr Cory Noble at cory.noble@zoetis.com.
The webinar will be presented by Jenny Helm Cert SAM Dip ECVIM-CA FHEA MRCVS EBVS and RCVS Specialist in Small Animal Medicine.
Jenny will explain the latest knowledge about lungworm in dogs, including an update on prevalence, clinical case management and treatment and prevention options.
Louise Longstaff, National Veterinary Manager at Zoetis said: “Jenny will not only cover some of the challenges with diagnosing lungworm but will also discuss the latest prevention strategies including the use of Simparica Trio."
https://cloud.mc.zoetis.com/LungWormWebinar2025
Zoetis says AI Masses delivers fast, accurate, in-clinic screening of common lymph node and skin/subcutaneous masses in minutes, making Vetscan Imagyst the most capable veterinary AI analyser in the world.
AI Masses uses an algorithm to identify and classify common skin/subcutaneous mass and lymph node aspirates at the point of care.
At additional charge, for added diagnostic confidence, Zoetis also offers expert clinical pathologist reviews via Digital Cytology and Add-on Expert Review within hours.
Abhay Nayak, President, Global Diagnostics at Zoetis said: “By empowering veterinary teams with valuable insights into potentially cancerous cells, we are helping to reduce waiting times and alleviate stress for pet owners facing some of the most challenging moments with their beloved pets.
https://www.zoetisdiagnostics.com/uk/point-of-care
This, the company says, makes Simparica Trio the only oral moxidectin that is licensed to treat A.vasorum in dogs in the UK.
Louise Longstaff, National Veterinary Manager at Zoetis UK said: “The last time a product was licensed for the treatment of lungworm in the UK was some time ago, so this is an especially important development.
"Simparica Trio offers a new licensed route of administration for lungworm treatment in dogs, giving vets another option to that which is currently available.
"It enables them to tailor treatment based on their patient’s needs while still prescribing within the cascade.”
Simparica Trio is a chewable monthly tablet for dogs containing sarolaner, moxidectin and pyrantel.
It kills fleas and ticks, treats mites, roundworm and hookworm, prevents and treats lungworm and prevents heartworm disease.
https://www.noahcompendium.co.uk/?id=-485011
There are four events: two webinars, a face-to-face event with a workshop and a presentation at this year’s BVNA Congress.
The first webinar: ‘OA pain, awareness and management: how veterinary teams can collaborate to effectively manage OA’, takes place on Thursday 7th August (7-8pm).
The second webinar: ‘Librela clinical update; 4 years of clinical experience’ is on Tuesday 19th August (7-8pm).
The face-to-face event: ‘OA pain, awareness and management: how veterinary teams can collaborate to effectively manage OA’ and ‘Librela clinical update; 4 years of clinical experience’ plus practical application workshops, is on Saturday 6th September (10am-1pm) at BVNA HQ Harlow, Essex.
Finally, the BVNA Congress presentation: ‘The Joint Approach; the importance of the nursing team in OA diagnosis and management is on Sunday 12th October (9-10am) and it is free for everyone.
Jayne Clark, Zoetis National Veterinary Manager, Pain. “We are aiming for the talks to enhance delegates’ confidence in navigating aspects of pain management in dogs and cats so that they can support pet and owners with the latest knowledge, in a highly informed, confident and objective way.”
https://bvna.org.uk/events
Zoetis says that the problem appears not to be an endemic wellbeing issue for which the answer might be to develop greater individual resilience, but rather it is a symptom of the working environment itself, fuelled by structural, cultural and economic factors.
This, the company argues, means that concentrating on individual resilience may be misguided, and a new approach is needed, one that addresses the environmental factors at play.
The white paper identifies three areas for change:
Firstly, a complete reimagining of the veterinary workplace with more flexible and sustainable working models.
This includes considering more flexible work rotas, using technology to ease workloads, and enhancing the supporting role of veterinary nurses.
Indeed the most important factor in improving workplace wellbeing and professional satisfaction, cited by 27% of vets, was to better train veterinary nurses to take on more responsibility.
Secondly, finding ways to adapt to meet growing and varied client needs.
The white paper recommends enhancing communication training, adopting technology for better client management, and offering more support for vets when managing emotionally challenging conversations with clients.
Finally, the paper calls for a rethink over how vets are selected for in the first place.
Currently, the profession draws from a pool of 96% white, 29% fee-paying, largely female people who are not representative of the market they serve.
Greater diversity in the profession, Zoetis says, delivers social benefits, strategic advantages and workplaces with broader perspectives and greater psychological safety.
Stephanie Armstrong, Regional President at Zoetis, said: “Addressing retention in the veterinary field requires looking beyond individual well-being to systemic factors.
"By fostering better work environments and providing support, we can help ensure that veterinarians continue to provide vital services to our communities.”
Zoetis is urging stakeholders across the veterinary and animal health sector to review the white paper’s insights and join a collective effort to implement solutions.
https://www2.zoetis.co.uk/about-zoetis/news-media/knowledge-hub/transforming-veterinary-practice-for-the-21st-century
The one-hours session: "How do you recommend parasite treatments to your clients?" will be presented by Zoetis Veterinary Consultant Ruth Moxon MVB MRCVS.
Ruth will discuss how to structure advice and how to take the conversation away from the idea of ‘selling’ and towards a confident recommendation based on the pet’s needs.
The course will cover:
Ruth said: “We are aiming for attendees to leave the session feeling confident about discussing recommendations to clients on parasiticides.
"The talk will enable them to comfortably explain the features and benefits of the right parasiticide for that pet and owner in an objective way.”
The course is free to BVNA members.
Non-members are welcome to join the webinar at a cost of £15.00 per ticket.
To book, email: cpd@bvna.co.uk
Photo: BVNA
The company says AI Masses will allow veterinary professionals to analyse lesions suggestive of cancer in-clinic and with a fast turnaround.
The AI technology, which has been trained by human clinical pathologists, should enable individualised treatment outcomes earlier for more cases.
Zoetis says AI Masses only needs a single round of sample preparation and the results can, at additional cost, be supplemented with an expert review from a network of specialists through Zoetis’ Virtual Laboratory.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer at Zoetis said: “Waiting for results can be stressful for pet owners – even more so when it involves a cancer screening.
"Our research shows that up to 75% of pet owners find abnormal results highly stressful.1
"AI Masses is yet another point-of-care capability to deliver results in-clinic, further exemplifies Zoetis’ purpose to advance care for animals, shortening anxious wait times to allow for faster care decisions that help provide the best possible outcome.”
Pre-orders will be announced for US customers in Q2 2025.
VetSurgeon.org understands AI Masses will be coming to the UK some time in 2025.
https://www.zoetisdiagnostics.com
The guidance was written by Hany Elsheikha, Head of the European Scientific Counsel for Companion Animal Parasites (ESCCAP).
For a copy of the bulletin, contact your Zoetis Account Manager or call Customer Support on 0345 300 8034.
The refreshed packaging keeps the same colour scheme, but the graphics indicating the product uses stand out better.
The company has also added an area on the side of the carton for owners to note the date each dose is given.
What can I say, it's a slow news day.
98 veterinary surgeons from around the UK took part in the survey.
The survey did not ask respondents to define what they considered to be a mental health issue.
However, 29% 'very much agreed', and 39% 'somewhat agreed' that 'my mental health impacts my work as a veterinarian'.
83% said the main factor behind mental health problems in the profession is general burnout, 80% said work intensity, 74% the lack of work/life balance, 49% being undervalued by clients, 40% being undervalued by management, 37% a lack of mental health support in practice, 30% financial concerns, and 26% said a lack of HR or structured management in practice.
57% of vets said they know other vets with mental health issues.
64% said they believe there isn’t enough mental health support within the profession.
97% say work-related mental health issues have negatively impacted their job satisfaction.
78% said they would like to see more accessible content on mental health within the industry and 49% think the topic needs to be spoken about more.
64% of vets said they would welcome counselling, 64% support with burnout recovery and 61% wanted training on coping tactics at university.
Stephanie Armstrong, Senior Vice President at Zoetis and Independent Council Member for The Royal Veterinary College said: “Having worked in the industry for many years, I know what an incredible profession it is, but unfortunately, I am also acutely aware of the heavy mental health load many vets face.
"The Zoetis Foundation continues to support VetLife and other initiatives aimed at caring for vets - our ambition is to work together with policy makers, industry leads and educators to offer new solutions and ensure the future prognosis of the profession is a healthy one.”
The company now expects the vaccine will not be available until June 2025.
The company apologised for the disruption and inconvenience and says it will provide more information as soon as it becomes available.
For further information contact your Zoetis Account Manager or call Head Office on 0345 300 8034.
Zoetis says the Vetscan OptiCell represents a significant leap forward in technology and offers meaningful time, cost and space savings for veterinary healthcare teams, contributing to better patient outcomes and a more efficient clinic workflow.
It uses cell-focusing and AI-powered classification technology for CBC analysis, delivering a claimed lab quality accuracy at the point of care.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis said: “Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint.
"For the first time, we are able to use advanced AI image recognition technology to characterise the blood cells instead of relying on their size or other physical parameters.”
Pre-orders will be available in the UK later this year.
Zoetis, which has a portfolio of drugs for companion animals, including Apoquel, Cerenia, Convenia, Cytopoint, Librela and Simparica, says it will be sharing knowledge with BVNA members via webinars, regional CPD events and the Veterinary Nursing Journal (VNJ), and supporting the 2024 BVNA Congress.
Zoetis says the educational aspect of the partnership was developed after its market research showed that 8 in 10 veterinary nurses were interested in CPD support on the topic of parasiticides.
Louise Longstaff, National Veterinary Manager - Companion Animal, at Zoetis, said: "Veterinary nurses, alongside veterinary care assistants, all play a key role in the ongoing health and welfare of clients’ pets and as the backbone of every practice, they are to be applauded for all that they do.
"We are delighted to be able to announce this new initiative so soon after Veterinary Nursing Awareness Month and are proudly looking forward to delivering to the extended needs of RVNs as a reflection of our recent market research.”
BVNA President Lyndsay Hughes said: “We are delighted to collaborate with Zoetis on this new initiative.
"This partnership fully aligns with our commitment to promote the vital work of veterinary nurses in upholding animal welfare, plus those in wider veterinary care roles.
"We look forward to working together to enhance our offering to BVNA members, across many of our educational activities as an association.”
The company says the new addition leverages a combination of image recognition technology, algorithms, and cloud-based deep learning AI to enable accurate, in-clinic sediment analysis of fresh urine, delivering results within minutes.
The system evaluates red and white blood cells, squamous and other epithelial cells (e.g. urothelial and renal tubular epithelial cells), hyaline and non-hyaline casts, struvite and calcium oxalate dihydrate crystals, and cocci and rod bacteria.
Zoetis says its performance is comparable to that of a clinical pathologist.
Richard Goldstein, DVM, DACVIM, DECVIM-CA, Vice President and Chief Medical Officer, Global Diagnostics Medical Affairs at Zoetis said: “Urinalysis is an essential diagnostic test for veterinary surgeons, and often a good indicator of potential wider issues.
"Having the ability to get these results faster will improve the speed and level of care teams can provide their patients, facilitating efficient medical decision-making and helping to ensure smooth workflows.
Practices which want to buy the alternative imported vaccine will need to apply to the VMD for a Special Import Certificate (SIC).
Wholesalers have agreed to stock the alternative vaccine.
Zoetis says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working hard to resume Equip Rotavirus supply as soon as possible.
For further information, contact your Zoetis account manager or ring Zoetis HQ on 0345 300 8034.
Zoetis has added a dermatology application to its Vetscan Imagyst, which promises to reduce the time it takes GP veterinary surgeons to analyse skin samples by as much as half.The new Vetscan Imagyst AI dermatology application analyses impression smears and ear and skin swabs to identify yeast, inflammatory cells and bacteria.
It provides results in about ten minutes, depending on your upload speeds, which VetSurgeon understands is probably how long a dermatologist would take to perform the task (compared to a GP, who might take twice as long, depending on skills, available equipment, volume of tests, etc).
In terms of accuracy, Zoetis says the application is comparable to that of a clinical pathology expert.
In addition, it fires out a report, including images, which can be shared with the client, adding more value to the consultation.
According to a 2006 study, something like 72% of vets' derm diagnosis and treatment recommendations are based on presenting clinical signs and physical examination alone1.
Vetscan Imagyst list price is just shy of £18,000, but there are a variety of commercial deals that can be discussed with your Zoetis Account Manager. Each AI analysis costs in the order of a tenner.
So the question is whether the new system is worth the investment - for the 72% in terms of a more accurate diagnosis over an educated guess, and for the 28% in terms of the time-savings over a manual analysis.
Sophie Duguid, Diagnostics National Veterinary Manager at Zoetis UK said: “The ability to accurately and reliably identify inflammatory cells, bacteria and yeast, at the time of visit can make a huge difference for busy clinics, ensuring better outcomes and happier patients and owners.
"Performing cytology is a critical component of the dermatology work-up, however this can often be challenging for veterinary healthcare teams to deliver given the considerable time pressures in clinical practice.
"Vetscan Imagyst AI dermatology allows clinicians to rapidly detect the presence or absence of skin infection in canine and feline dermatology cases which allows for clinically informed decision making."
Hill PB et al; Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Veterinary Record (2006) 158, 533-539
Zoetis has announced a supply problem with Equip Artervac, its vaccine against equine viral arteritis
The current inventory of Equip Artervac has an expiry date of March 29, 2023 and the company is not expecting a new batch to be available until the end of September 2023.
Zoetis says it has been working with relevant organisations to implement a plan to mitigate the impact on breeders.
The Thoroughbred Breeders Association has published advice for a blood sampling scheme at: https://www.rossdales.com/news-events/tba-members-equine-vaccine-advice-regarding-disruption-to-supply-of-equip-artervac, but Zoetis highlights that the advice requires action two weeks after the most recent EVA vaccination.
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0345 300 8034
The webinar will take place at 11am and will be repeated at 7.30pm for those who are unable to listen during the day.
Hosted by Zoetis vet Dr Wendy Talbot the session will last for approximately an hour and equates to 8 AMTRA CPD points.
Wendy will explain the current situation and recommended approaches to help slow resistance.
The webinar will conclude with a live Q&A to give everyone the opportunity to discuss any queries, concerns or common questions they hear from their customers with Wendy.
Zoetis Equine Product Manager, Penny McCann said: "Our webinars continue to be very well received.
“This one is particularly important as it explains the important new thinking around the use of anthelmintics in order to address the serious challenge of resistance.
"It’s a must for all those involved with prescribing.”
To book the 11am webinar: https://register.gotowebinar.com/register/6163460189961597967 To book the 7.30pm webinar: https://register.gotowebinar.com/register/6394015684169009164
The acquisition of Jurox brings Zoetis a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals and high-quality local R&D and manufacturing operations in Australia.
Stephanie Armstrong, Senior Vice President and Cluster Lead UK, BeNeLuX, Nordics & Ireland, said: “We are grateful to the O’Brien family for entrusting the future of this family-owned business to Zoetis.
"Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners.
"With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio here in the UK and Ireland.”
www.jurox.com
Using practices developed for human healthcare measurement, NewMetrica developed VetMetrica, which the company says can measure how an animal “feels” about its circumstances from its individual perspective.
Jim Brick, Vice President Commercial Development and Lifecycle and Innovation at Zoetis said: "This novel approach supports a significant shift in veterinary care and animal welfare more generally towards the attainment of good or excellent quality of life in companion animals.
"The benefits of NewMetrica’s digital instruments have been validated through scientific publications and the FDA, and the EMA has confirmed the algorithms that produce the results.”
Jamie Brannan, President International Operations, Zoetis added: "We expect NewMetrica’s tools and algorithms to support earlier detection and treatment of diseases as we gain more insight into the quality of life of our pets and be an important element of future product development.
“NewMetrica’s instruments will give us scientifically validated results for alleviation of OA pain that veterinarians and pet owners will appreciate and value.”
https://www.newmetrica.com
Apoquel chewable tablets were approved by the Veterinary Medicines Directorate (VMD) in November 2021.
Apoquel Chewable contains the same active ingredient, at the same dosing regime, for the same indications as original Apoquel, but in a palatable formulation which, in a field-study of client-owned dogs, was found to have a 91.6% acceptance rate.1
Dr Carly Mason, President of the British Veterinary Dermatology Study Group (BVDSG), said: “The new chewable form of Apoquel provides owners with a means of controlling itch using a tablet that can be given like a treat or mixed with a meal, making it much easier for owners and more acceptable to their pet.
“In many cases, the chewable formulation will be the obvious first-line Apoquel for veterinarians to prescribe to control canine itching while the underlying cause of allergic dermatitis is investigated.”